Download MendeleyAn SP110-SP100 axis is a critical regulator of promyelocytic leukaemia body dynamics and mitotic fidelity.
Aird, E.J., Rabl, J., Knuesel, T., Groen, K., Awwad, S.W., Korablev, B., Scherpe, L., Al-Herz, W., Hupfer, R., Recher, M., Jackson, S.P., Hale, B.G., Corn, J.E.(2026) Nat Cell Biol 28: 684-695
- PubMed: 41826696 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s41556-026-01916-w
- Primary Citation Related Structures:
9TNZ - PubMed Abstract:
Stimulation of the innate immune system by foreign RNA elicits a potent interferon response and can trigger cell death. The mechanisms by which cells balance a robust response with cell-intrinsic lethality are still being uncovered. Here, using genome-wide CRISPR-Cas9 genetic screens with triphosphorylated RNA stimulation, we discover that promyelocytic leukaemia (PML) nuclear body-localized speckled protein 110 (SP110) is a potent inhibitor of type 1 interferon-driven cell death. Death suppression by SP110 counteracts a toxic activity of SP100, a major constituent of PML bodies. Loss of SP110 leads to mitotic retention of SP100 and PML bodies, which associate with and perturb segregating chromosomes, leading to micronucleus formation, DNA damage and genotoxic cell death. A combination of cryo-electron microscopy, AlphaFold modelling and cellular biochemistry reveals that SP110 dissolves toxic SP100 oligomers via necessary and sufficient direct interactions between their caspase activation and recruitment domains. These data reveal the critical roles of SP100 and SP110 in governing the disassembly of PML bodies during mitosis, as well as the repercussions if this process is misregulated.
- Institute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zurich, Switzerland.
Organizational Affiliation:
